HDM1005 vs. Mazdutide: New Phase 3 Trial for Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by high blood sugar. Many patients struggle to achieve adequate glycemic control even with standard treatments like metformin alone or in combination with sodium-glucose cotransporter 2 (SGLT2) inhibitors (drugs that help the kidneys remove sugar from the body). This ongoing challenge highlights the need for new, effective therapeutic options. This Phase 3 study aims to evaluate the efficacy and safety of a novel compound, HDM1005, against an active comparator, Mazdutide, in T2DM patients with inadequate glycemic control.

As this study is currently "NOT_YET_RECRUITING" (estimated start March 2026, completion December 2027), there are no results or specific data available yet. However, the trial is designed to determine if HDM1005 can provide superior or non-inferior glycemic control compared to Mazdutide. Researchers will primarily assess changes in HbA1c (a measure of average blood sugar over several months) from baseline. Secondary endpoints will likely include body weight changes, fasting plasma glucose, and safety parameters. The primary objective is to compare the change in HbA1c from baseline after 52 weeks of treatment between HDM1005 and Mazdutide in patients with T2DM inadequately controlled by existing therapies.